Keyphrases
Paclitaxel
100%
Group Studies
100%
Gynecologic Oncology Group
100%
Etoposide
100%
Phase I Trial
100%
Recurrent Ovarian Carcinoma
100%
Starting Dose
33%
Measurable Disease
33%
Phase I Study
16%
Maximum Tolerated Dose
16%
Ovarian Cancer
16%
Granulocyte Colony-stimulating Factor (G-CSF)
16%
Previously Treated
16%
Complete Response
16%
Consecutive Days
16%
Recurrent Ovarian Cancer
16%
Previous Chemotherapy
16%
Myelosuppression
16%
Carbohydrate Antigen 125 (CA125)
16%
First Cycle
16%
Severe Neutropenia
16%
Sequence-dependent
16%
Alternating Cycle
16%
Growth Factor Support
16%
Myelosuppressive
16%
Patient Dose Reduction
16%
Medicine and Dentistry
Paclitaxel
100%
Krukenberg Tumor
100%
Gynecological Oncology
100%
Etoposide
100%
Phase I Trials
100%
Diseases
33%
Neutropenia
16%
Growth Factor
16%
Ovarian Cancer
16%
Patient History of Chemotherapy
16%
Recurrent Ovarian Cancer
16%
Granulocyte Colony Stimulating Factor
16%
Bone Marrow Suppression
16%
Drug Dose Reduction
16%
CA-125
16%
Pharmacology, Toxicology and Pharmaceutical Science
Paclitaxel
100%
Etoposide
100%
Ovary Carcinoma
100%
Phase I Trials
100%
Ovary Cancer
33%
Diseases
33%
Neutropenia
16%
Maximum Tolerated Dose
16%
Granulocyte Colony Stimulating Factor
16%
Growth Factor
16%
Patient History of Chemotherapy
16%
Bone Marrow Suppression
16%